, 2 ‐ a ] benzimidazoles Which Are E ffi cacious in an in Vivo Mouse Model of Malaria

Structure−activity relationship studies involving N-aryl-3-trifluoromethyl pyrido[1,2-a]benzimidazoles (PBI) identified several compounds possessing potent in vitro activities against the asexual blood, liver, and gametocyte stages of the Plasmodium parasite with no cross-resistance to chloroquine. Frontrunner lead compounds with good in vitro absorption, distribution, metabolism, and excretion (ADME) profiles were subjected to in vivo proof-of-concept studies in NMRI mice harboring the rodent P. berghei infection. This led to the identification of compounds 10 and 49, effecting 98% and 99.93% reduction in parasitemia with mean survival days of 12 and 14, respectively, at an oral dose of 4 × 50 mg/kg. In vivo pharmacokinetics studies on 10 revealed slow absorption, low volume of distribution, and low clearance profiles. Furthermore, this series displayed a low propensity to inhibit the human ether-a-go-go-related gene (hERG) potassium ion channel whose inhibition is associated with cardiotoxicity.

[1]  A. Blagborough,et al.  Antimalarial Transmission-Blocking Interventions: Past, Present, and Future. , 2018, Trends in parasitology.

[2]  J. Keiser,et al.  Antischistosomal Activity of Pyrido[1,2-a]benzimidazole Derivatives and Correlation with Inhibition of β-Hematin Formation. , 2017, ACS infectious diseases.

[3]  K. Chibale,et al.  Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model. , 2017, Journal of medicinal chemistry.

[4]  T. Ioerger,et al.  N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis , 2016, Proceedings of the National Academy of Sciences.

[5]  F. Supek,et al.  Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease , 2015, PLoS pathogens.

[6]  R. Price,et al.  Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria , 2014, Malaria Journal.

[7]  Kelly Chibale,et al.  Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis. , 2014, Chemical reviews.

[8]  Alexander Tropsha,et al.  Tuning HERG out: antitarget QSAR models for drug development. , 2014, Current topics in medicinal chemistry.

[9]  Erika L. Flannery,et al.  Antimalarial drug discovery — approaches and progress towards new medicines , 2013, Nature Reviews Microbiology.

[10]  D. Caridha,et al.  The metabolism of primaquine to its active metabolite is dependent on CYP 2D6 , 2013, Malaria Journal.

[11]  Manish P. Patel,et al.  Microwave-assisted synthesis of pyrido[1,2-a]benzimidazole derivatives of β-aryloxyquinoline and their antimicrobial and antituberculosis activities , 2013, Medicinal Chemistry Research.

[12]  X. Su,et al.  Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. , 2012, The Lancet. Infectious diseases.

[13]  R. Price,et al.  Primaquine radical cure of Plasmodium vivax: a critical review of the literature , 2012, Malaria Journal.

[14]  T. Wellems,et al.  The threat of artemisinin-resistant malaria. , 2011, The New England journal of medicine.

[15]  J. A. Spicer,et al.  Inhibition of the cellular function of perforin by 1-amino-2,4-dicyanopyrido[1,2-a]benzimidazoles. , 2011, Bioorganic & medicinal chemistry.

[16]  Albert J Ndakala,et al.  Antimalarial pyrido[1,2-a]benzimidazoles. , 2011, Journal of medicinal chemistry.

[17]  Peter D. Crompton,et al.  Advances and challenges in malaria vaccine development. , 2010, The Journal of clinical investigation.

[18]  A. Kitamura,et al.  Novel Pyridobenzimidazole Derivatives Exhibiting Antifungal Activity by the Inhibition of β-1,6-Glucan Synthesis. , 2010 .

[19]  J. Baird,et al.  Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. , 2010, Trends in parasitology.

[20]  F. Cox.  History of the discovery of the malaria parasites and their vectors , 2010, Parasites & Vectors.

[21]  P. Alonso,et al.  New medicines to improve control and contribute to the eradication of malaria. , 2009, Nature reviews. Drug discovery.

[22]  A. Kitamura,et al.  Discovery of a Small-Molecule Inhibitor of β-1,6-Glucan Synthesis , 2008, Antimicrobial Agents and Chemotherapy.

[23]  B. Small,et al.  Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. , 2006, Journal of pharmacological and toxicological methods.

[24]  P. Olliaro,et al.  Antimalarial compounds: from bench to bedside , 2003, Journal of Experimental Biology.

[25]  Robert G. Ridley,et al.  Medical need, scientific opportunity and the drive for antimalarial drugs , 2002, Nature.

[26]  R. Markus,et al.  Tertian and Quartan Fevers: Temporal Regulation in Malarial Infection , 2001, Journal of biological rhythms.

[27]  T. Egan,et al.  Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity. , 2000, Journal of medicinal chemistry.

[28]  D. Sullivan,et al.  On the molecular mechanism of chloroquine's antimalarial action. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Sauerwein,et al.  Experimental human challenge infections can accelerate clinical malaria vaccine development , 2010, Nature Reviews Immunology.